fumo attivo, fumo passivo e farmaci centro antifumo (interdipartimentale) aou policlinico di modena...
TRANSCRIPT
Fumo attivo, fumo passivo e farmaci
Centro Antifumo (interdipartimentale) AOU Policlinico di ModenaStruttura Complessa di Farmacologia e Tossicologia Clinica
(Direttore: Prof. A. Tomasi)
Maria Michela Cainazzo, Ilaria Tiraferri
Modena, 24 Maggio 2011
La nicotina (C10H14N2) è una sostanza dotata di forte lipofilia e ciò le consente, indipendentemente dalla via di assunzione, di attraversare la b.e.e. e di raggiungere rapidamente il Sistema Nervoso Centrale (SNC) a livello del quale esplica le sue funzioni eccitatorie.
N
N
CH3
si accumula prevalentemente a livello cerebrale, epatico, renale e nel tessuto adiposo
Struttura e metabolismo della nicotina nell’uomo
La principale via di metabolizzazione della nicotina è la C-ossidazione epatica; circa il 70-80% della dose di nicotina inalata viene metabolizzata a cotinina; quest’ultima è ulteriormente metabolizzata a trans-3’idrossicotinina. Ambedue le reazioni sono catalizzate dal CYP2A6.
esposizione regolare al fumo passivo aumenta del 99% il rischio di sdr coronarica acuta
aumento del 20-30% del rischio di insorgenza di neoplasie polmonari
peggiora le patologie polmonari preesiste
aumento del 40% di sviluppare il diabete
sindrome da distress respiratiorio infantile
riacutizzazione di asma e patologie orecchio medio (otite media) nei bambini
aumento del rischio di eventi cardiaci fatali e non fatali
Rischi associati al fumo passivo
Per interazione tra farmaci si intende il fenomeno che si realizza quando gli effetti (tossici o terapeutici) di un farmaco A sono modificati dalla precedente o concomitante assunzione di uno o più agenti farmacologici (B, C...)
Il fenomeno può divenire clinicamente significativo qualora la risposta globale successiva alla somministrazione ravvicinata o simultanea di due o più composti è marcatamente diversa dalla semplice somma degli effetti che ciascun composto avrebbe esercitato se dato individualmente o dagli effetti che il composto principale avrebbe avuto se somministrato da solo.
Interazioni tra farmaci
Sono intese come una modifica o un’alterazione dell’assorbimento, della distribuzione (trasporto), del metabolismo o della escrezione di un farmaco (A) sotto l’influenza di un secondo farmaco (B). Le interazioni farmacocinetiche sono quelle con maggiore significato clinico.
Interazioni farmacocinetiche
Interazioni farmacodinamiche
Le interazioni farmacodinamiche sono definite come una modifica della risposta farmacologica di un farmaco A in seguito all’azione diretta o indiretta di un farmaco B a livello del recettore o della funzione, senza modifica concomitante delle concentrazioni dei farmaci in causa.
CYP3A4
CYP2D6
CYP2B6
CYP2C9
CYP2C19
Sono i principali enzimi appartenenti al complesso enzimatico del citocromo P450 responsabili del 90% del metabolismo ossidativo dei farmaci
Gli enzimi del citocromo P450 sono presenti in quasi tutti i tessuti, il contenuto enzimatico maggiore, espresso in nmol/mg di proteine microsomiali, è nel fegato; i CYPs si localizzano, anche, in intestino, polmone, rene, ghiandole surrenali, cervello, cuore, gonadi, mucosa tracheale e cute. Nel genoma umano sono stati individuati 57 geni codificanti per i CYP; sono geni polimorfi, le cui numerosi varianti alleliche possono codificare enzimi funzionalmente inefficaci; la conseguenza della ridotta attività enzimatica si manifesta con la comparsa di reazioni avverse nell’individuo (elevate concentrazioni plasmatiche).
Relative abundance of individual CYP forms in the liver and some examples of substrates, inhibitors and inducers. CYPs with clinically significant genetic polymorphism in gray. Phenob. phenobarbital, TCDD 2,3,7,8-tetrachlorodibenzo-p-dioxin, nk not known
Pelkonen O. et al, 2008
Le interazioni clinicamente evidenti tra fumo di sigaretta e farmaci possono essere interazioni di tipo farmacocinetico oppure interazioni di tipo farmacodinamico
Gli idrocarburi aromatici policiclici, potenti induttori del citocromo P450, sono responsabili delle interazioni farmacocinetiche
La nicotina può causare le interazioni farmacodinamiche
Il fumo di sigaretta ha effetto variabile sulla concentrazione plasmatica di amitriptilina e nortriptilina; non ha nessun effetto sul clordiazepossido; modifica poco la concentrazioni plasmatica della carbamazepina per le proprietà specifiche di autoinduzione epatica del farmaco.
Idrocarburi aromatici policiclici
Desai HD, et al., 2001
Role of human UGT2B10 in N-glucuronidation of tricyclic antdeprassant, amitripyline, imipramine, clomipramine, and trimipramine
Zhou D, Guo J, Linnenbach AJ, Booth-Genthe CL, Grimm SWDrug Metab Dispos 38(5):863-70, 2010
Nicotine was found to selectivity inhibit UGT2B10 but not UGT1A4 activity. At a low tricyclic antideprassant concentration, nicotine inhibited their glucuronoconidation by 33 to 50% in human liver microsomes. Our results suggest that UGT2B10 is a high-affinity enzyme for tricyclic antidepressant glucuronidation and is likely to a major UGT isoform responsible for the glucuronidation of these drugs at therapeutic concentration in vivo
Effects of nicotine on cytochrome P4502A6 and 2E1 activities Hukkanen J et al.
British J of Clinical Pharmacol 2009; 69:152-159
Smoking slows the metabolism of nicotine and accelerates the metabolism of chlorzoxazone; nicotine is a useful probe for CYP 2A6 activity; chlorzoxazone is a frequently used probe for CYP 2E1 activity; the tobacco smoke constituents responsible of those modifications are unknown
Human CYP2A6 and CYP2E1 are not affected by nicotine. High-dose nicotine treatment has a low potential for interaction with CYP2A6 CYP 2 E1 substrates
Chronic smoking inhibits CYP 2A6-mediated metabolism; there are substances in tobacco smoke, as yet unidentified, that inhibit the metabolism of nicotine
INITIATION
PROPAGATION
CLOT FORMATION
ANTHITROMBIN
Il fumo di sigaretta accelera la clereance dell’eparina; si riduce, pertanto la quota di eparina che potenzia l’attività dell’antitrombina (ATIII); l’eparina normalmente incrementa l’intensità della reazione trombina-antitrombina, che porta alla formazione di un complesso ATIII-T inattivato in grado di inibire il fattore Xa e IIa. L’aumentata eliminazione dell’eparina può causare trombofilia.
EPARIN
Median C-peptide-corrected insulin concentratio-time profiles in the presence and absence of passive smoke exposure. EXU, inhaled human insulin (Exubera). Passive smoke + EXU ( ); EXU 3 mg alone ( ).
Acute passive cigarette smoke exposure and inhaled human insulin pharmacokineticsFountaine R. et al.
British J of Clinical Pharmacol 2007; 65:864-870
Acute passive cigarette smoke exposure and inhaled human insulin pharmacokineticsFountaine R. et al.
British J of Clinical Pharmacol 2007; 65:864-870
Active cigarette smoking is associated with increased permeability of the pulmonary alveolar epithelium, resulting in faster absorption of inhaled drugs such as inhaled human insulin; its absorption is increased approximately twice to four times as much in chronic smokers compared with nonsmokers
Passive smoke exposure causes a decrease in lung permeability, an effect opposite to that of active smoking
Acute passive smoke exposure results in a decrease in inhaled human insulin bioavaibility and does not create a risk of hypoglicemia
Effect of smoking cessation, acute re-exposure and nicotine replacement in smokers on AIR inhaled insulin pharmacocokinetics and glucodynamicsPan A.X. et al.
British J of Clinical Pharmacol 2007; 65: 480-187
Effect of Cigarette Smoking and Cytochrome P450 2D6 Genotype on Fluvoxamine Concentration in Plasma of Japanese PatientsKatoh Y. et al.
Biol. Pharm. Bull. 2010; 33:285-288
Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic diseaseSugahara H. et al.
Eur. J. Pharmacol 2009; 65:699-704
Chronic exposure to nicotine and saquinavir decreases endothelial Notch-4 expression and distrupt blood-brain barrier integrity
Manda V.K. et al.
J of Neurochemistry 2010; 115:515-525
Chronic administration of nicotine, saquinavir and ritonavir or the combination of drugs create ROS in vivo in brain tissue, measured by fluorescence emitted by DHE. The upper panel in (a) shows the qualitative images for the ROS generated in control and treatment groups. The fluorescent quantification of the ROS was shown in lower panel. *** indicate p < 0.001. To see whether ROS is associated with blood vessels, brain sections were stained with CD31 and the representative pictures both at lower and higher magnification were shown in panel (b).
Chronic exposure to nicotine and saquinavir decreases endothelial Notch-4 espressione and distrupt blood-brain barrier integrityManda V.K. et al.
J of Neurochemistry 2010; 115:515-525
Chronic administration of saquinavir, ritonavir in presence of nicotine and cigarette smoke extract at pharmacological doses results in BBB disruption as evidenced by an increased brain distribution volume of the vascular impermeant marker [14C]-sucrose. In this experiment, concurrent exposure to nicotine and the protease inhibitor resulted in a significantly greater volume of distribution for [14C]-sucrose than control animals and or the chronic administration of either alone. This data strongly suggests the BBB is disrupted during chronic nicotine and protease inhibitor administration. All data represent the mean ± SEM, n = 4–6 independent experiments. *** indicates significance at a value of p < 0.001.
Carbamazepina but not valproate induces CYP2A6 activity in smokers with mental illnessWilliams JM et al. Cancer Epidemiol Biomarkers Prev 2010; 19: 2582-9
CONCLUSIONS Carbamazepine likely induces hepatic metabolism via CYP2A6 and is associated with increased 3HC/cotinine ratios. Increased nicotine metabolism in individuals using AED has implications for increased smoking behavior and exposure to more tobacco toxins
3HC/cotinine ratios in smokers taking carbamazepine (CBZ; n= 14) versus those not taking it (n= 135) in total sample and mental health subgroups. OCB, oxcarbazepine; SCZ, schizophrenia; BPD, bipolar disorder. **P < 0.001; *P < 0.05, Mann-Whitney test.
3HC/cotinine ratios in smokers taking valproic acid (n = 40) versus those not taking it (n= 109) in total sample and mental health subgroups
Interazioni farmacodinamiche della nicotina
Contraccettivi ormonali Steroidi Beta-bloccanti Benzodiazepine Oppioidi
DATA SYNTHESIS: The summary risk estimates associated with current use of low-dose OCs were 1.84 [95% confidence interval (CI) = 1.38, 2.44] for myocardial infarctions and 2.12 (95% CI = 1.56, 2.86) for ischemic strokes. The overall summary odds ratio for both outcomes was 2.01 (95% CI = 1.63, 2.48). Second generation OCs were associated with a significant increased risk of both myocardial infarction and ischemic stroke events [1.85 (95% CI = 1.03,3.32) and 2.54 (95% CI = 1.96,3.28), respectively]; and third-generation OCs, for ischemic stroke outcome only [2.03 (95% CI = 1.15,3.57)].
CONCLUSIONS: In conclusion, a rigorous meta-analysis of the literature suggests that current use of low-dose OCs significantly increases the risk of both cardiac and vascular arterial events, including a significant risk of vascular arterial complications with third generation OCs
Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis.Baillargeon JP, McClish DK, Essah PA, Nestler JE.
J Clin Endocrinol Metab, 2005; 90: 3863-3870
Dexamethasone attenuation of the cortisol response to nicotine in smokersPomerleau OF, Pomerleaau CSPsychopharmacology 1990; 101:284-6
The dexamethasone condition was characherized by a pronunced suppression of baseline plasma cortisol, as expected and by a significant dampening of cortisol response to nicotine, indicating diminished sensitivity to nicotine under contiditions of enhaced corticosteroid activity.
Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthmaChaudhuri R et al.AM J Respir Crit Care Med, 2003; 168:1308-1311
Il fumo di sigaretta si associa ad aumento dei neutrofili nell’espettorato e ad una riduzione della risposta bronchiale agli steroidi assunti per via orale perchè nei fumatori si ha
TNF-α β recettori per i glucocorticoidi sulla superficie bronchiale attivazione di NF-kB
attività della deacetilasi a livello dell’istone; aumento dell’espressione genica dei mediatori della flogosi
Inhaled steroid/tobacco smoke particle interactions: a new light on steroid resistanceInvernizzi G. et al.Respiratory Research 2009; 10, 48-57
CONCLUSION: Our data suggest that particle interaction between inhaled BDP-HFA (beclomethasone-hydrofluoralkane) pMDI and ETS takes place in the first few seconds after drug delivery, with a decrease in smaller particles and a concurrent increase of larger particles. The resulting changes in aerosol particle profile might modify regional drug deposition with potential detriment to drug efficacy, and represent a new element of steroid resistance in smokers. Although the present study does not provide any functional or clinical assessment, it might be useful to advise smokers and non smokers with obstructive lung disease such as asthma or COPD, to avoid to act inhaled drugs in the presence of ETS in order to obtain the best therapeutic effect
Particles frequency of BDP-HFA pMDI delivered in ambient air (open columns) and in ETS (black columns). Particles sized 0.3–1.0 μm, which predominated in ambient air, were again no longer measurable in ETS, particles in the range of 1.0 to 3.0 μm in diameter being mostly represented.
Interazioni tra fumo di tabacco e farmaci
Grazie dell’attenzione